Form 4: Outlook Therapeutics Insider Buys Shares
Insider Transaction (Form 4)
Ghiath M. Sukhtian and 1 other reported changes in beneficial ownership of Outlook Therapeutics, Inc. common stock on August 12, 2026.
Summary
- Open-market purchase: acquired 2,525,252 Common Stock at $0.99 ($2,499,999) on August 12, 2026; holds 24,617,320 after (Indirect).
- Open-market purchase: acquired 2,525,252 Warrants (right to buy) on August 12, 2026; holds 2,525,252 after (Indirect).
Sentiment
Score: 9
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $2,499,999, committing personal capital to the stock.
Insider Transactions
Ghiath M. Sukhtian — Director, 10% owner
GMS Ventures & Investments — Director, 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Open-market purchase | Common Stock | 2,525,252 | $1 | $2.5M | 24,617,320 |
| 2026-08-12 | Open-market purchase | Warrants (right to buy) | 2,525,252 | — | — | 2,525,252 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Open-market purchase (2,525,252 shares) |
| 2026-08-12 | Open-market purchase (2,525,252 shares) |
Keywords
insider transaction, Form 4, OTLK, Outlook Therapeutics, Inc., bullish, Ghiath M. Sukhtian, GMS Ventures & Investments
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.